Divis' Laboratories Share Price
₹6057.00
+30.50
(+0.51%)
as on
Divis' Laboratories Stock Performance
as on September 15, 2025 at 4:01 pm IST
Day's Low
Day's High
₹5,974₹6,065.5
1.37%
Downside
0.14%
Upside
52 Week's Low
52 Week's High
₹4,955₹7,071.518.19%
Downside
16.75%
Upside
Divis' Laboratories share price movements today
- Previous Close
- ₹6,026.50
- Open
- ₹6,011.00
- Volume
- 1.52L
- Upper Circuit
- ₹6,629.00
- Lower Circuit
- ₹5,424.00
- Day's Low - High
- ₹5,974 - ₹6,065.5
- 52 Week Low - High
- ₹4,955 - ₹7,071.5
Divis' Laboratories Historical Returns
- 1 Month Return
- -1.74 %
- 3 Month Return
- -9.43 %
- 1 Year Return
- + 10.54 %
- 3 Year Return
- + 69.49 %
- 5 Year Return
- + 86.69 %
Divis' Laboratories Fundamentals
as on September 15, 2025 at 4:01 pm IST
Market Cap
₹1,60,794.32 Cr
Return on Equity (ROE)
15.57
PE Ratio (TTM)
69.77
Return on capital employed (ROCE)
20.63
Industry PE ratio
42.36
Beta (LTM)
0.7
P/B Ratio
10.27
Dividend Yield
0.52
PEG Ratio
2.94
Quarterly Earnings Growth YOY
26.74
EPS (TTM)
82.68
Sector
Pharmaceuticals
Book Value
564.87
Technical Analysis
Bearish
View Technical Analysis
Divis' Laboratories Stock Valuation
as on September 15, 2025 at 4:01 pm IST
Divis' Laboratories in the last 5 years
Lowest (28.97x)
November 21, 2022
Industry (42.36x)
September 15, 2025
Today (69.77x)
September 15, 2025
Highest (90.48x)
December 4, 2024
Today’s Price to Earnings Ratio: 69.77x
Divis Laboratories Ltd vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Divis' Laboratories with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| HOLD | 1,60,794.32 | 17.34% | 0.50 | 2,191 | 9,360 | |
| BUY | 1,19,520.02 | 29.69% | 0.66 | 1,911 | 11,516 | |
| BUY | 47,896.72 | -3.67% | 0.78 | 1,429 | 15,261 | |
| HOLD | 33,234.67 | 2.17% | 0.53 | 698 | 5,616 | |
| BUY | 1,25,064.56 | 21.15% | 0.51 | 5,291 | 27,547 |
Analyst Recommendation on Divis' Laboratories Stock
Based on 29 analysts
39.29%
Buy
21.43%
Hold
39.29%
Sell
Based on 29 analysts, 39.29% of analysts recommend a 'HOLD' rating for Divis' Laboratories. Average target price of ₹6362.79
Source: S&P Global Market Intelligence
Divis' Laboratories Share Price Target
Get share price movements and forecasts by analysts on Divis' Laboratories.
What analysts predicted
5.05%UPSIDE
Target Price
₹6362.79
Current Price
₹6057
Analyzed by
29 Analysts
High
₹7750
Target
₹6362.79
Low
₹4250
Divis' Laboratories target price ₹6362.79, a slight upside of 5.05% compared to current price of ₹6057. According to 29 analysts rating.
Source: S&P Global Market Intelligence
Divis' Laboratories Stock's Interest Amongst Investors
Investment in Divis Laboratories Ltd Shares on INDmoney has dropped by -22.36% over the past 30 days, indicating reduced transactional activity.
Time period: to
Search interest for Divis Laboratories Ltd Stock has increased by 4% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:4% versus previous 30 day period
Divis Laboratories Ltd Quarterly Profit & Loss
Figures in Rupees Crores
Divis Laboratories Ltd Annual Profit & Loss
Figures in Rupees Crores
Divis Laboratories Ltd Cash Flow
Figures in Rupees Crores
Divis' Laboratories Stock Shareholding Pattern
Numbers in percentages
Mutual Funds that own Divis' Laboratories Stock
Check out the Mutual Funds with significant holdings in Divis' Laboratories.
Funds | Holdings | Shares Held | |
|---|---|---|---|
 SBI Equity Hybrid Fund Direct Growth | 2.94% | 3700000 | |
SBI Large Cap Fund Direct Growth | 3.2% | 2731710 | |
SBI Focused Fund Direct Plan Growth | 2.87% | 1770000 | |
 Axis ELSS Tax Saver Fund Direct Plan Growth Option | 1.91% | 1075888 | |
 Nippon India Pharma Fund - Direct Plan - Growth Plan | 7.34% | 1000031 |
Divis' Laboratories Earnings and Dividends
View detailed summary of the earnings and dividend history of Divis' Laboratories.
Divis Laboratories Ltd Earnings Results
Divis Laboratories Ltd’s net profit jumped 26.74% since last year same period to ₹545.00Cr in the Q1 2025-2026. On a quarterly growth basis, Divis Laboratories Ltd has generated -17.67% fall in its net profits since last 3-months.
Read More about Earnings ResultsDivis Laboratories Ltd Dividends May,2025
In the quarter ending March 2025, Divis Laboratories Ltd has declared dividend of ₹30.00 per share on 17 May 2025 - translating a dividend yield of 1.00%.
Read More about Dividends
Indices Featuring Divis' Laboratories Stock
Check stock indices that include Divis' Laboratories.
Insights on Divis Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 12.83% to 13.31% in Jun 2025 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, DIVISLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 18.01% to 19.74% in Jun 2025 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 51.89% of holdings in Jun 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.8% return, outperforming this stock by 70.7%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 9.39% to 9.32% in Jun 2025 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 2.67K Cr → 2.52K Cr (in ₹), with an average decrease of 5.3% per quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 662.0 Cr → 545.0 Cr (in ₹), with an average decrease of 17.7% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 months, DIVISLAB stock has moved down by -9.9%
About Divis Laboratories Ltd
Divis Laboratories Ltd's top products include APIs and intermediates for anti-infectives, cardiovascular, central nervous system, anti-diabetics, gastro-intestinal and anti-inflammatory treatments. The company is also a leader in the manufacture of custom synthesis and process development services for the global pharmaceutical industry.
Divis Laboratories Ltd is the proud owner of several popular brands, including Divis Life, Divis Pharma and Divis Health. Divis Life offers a range of health and wellness products, while Divis Pharma provides a wide range of APIs, intermediates and custom synthesis services.
Revenue: ₹2,410.00Cr as on June 2025 (Q1 FY26)
Net Profit: ₹545.00Cr as on June 2025 (Q1 FY26)
Listing date: 12 Mar, 2003
Chairperson Name: Ramesh B V Nimmagadda
| Organisation | Divis Laboratories Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| CEO | Ramesh B V Nimmagadda |
| E-voting on shares | Click here to vote |
FAQs
What is Divis' Laboratories share price today?
Divis' Laboratories share price today stands at ₹6057 as on . Divis' Laboratories share today touched a day high of ₹6065.5 and a low of ₹5974.
What is the 52 week high and 52 week low range for Divis' Laboratories share?
Divis' Laboratories touched a 52 week high of ₹7071.5 and a 52 week low of ₹4955. Divis' Laboratories share price today i.e. is trending at ₹6057, which is -14.35% down from its 52 week high and 22.24% up from its 52 week low.
What is Divis' Laboratories's market capitalisation today?
Divis' Laboratories market capitalisation is ₹1,60,794.32 Cr as on .
How to buy Divis' Laboratories shares?
To buy Divis' Laboratories shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for DIVISLAB or Divis Laboratories Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Divis' Laboratories shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is Divis' Laboratories trading volume today?
Divis' Laboratories trading volume is 1.52L as on . This means that 1.52L shares of Divis' Laboratories were bought and sold on the stock market during today's trading session.